Actualités

Amgen (AMGN) stock is in focus after safety concerns around its rare disease therapy Tavneos, including reported patient deaths in Japan, prompted regulators and partners to restrict new prescriptions and consider withdrawal in the U.S. See our latest analysis for Amgen. At a share price of $337.42, Amgen has seen its 90 day share price return fall 9.96%, even as its 1 year total shareholder return of 27.83% and 3 year total shareholder return of 70.14% point to stronger longer term...

Thomas Dittrich is the latest “boomerang” executive to return to a former employer as CFO. Over a decade ago he was the biotech company’s chief accountant.

The Japanese drugmaker that sells rare-disease medicine Tavneos said new patients will be able to get the drug, which carries risk of liver injury.

Amgen Inc. (NASDAQ:AMGN) is one of Louis Navellier’s top long-term stock picks. On May 14, Piper Sandler reiterated an Overweight rating on Amgen Inc. (NASDAQ:AMGN) but lowered the price target to $427 from $432. The new price target still represents significant upside potential as the research firm expects the company to deliver top-line revenue growth […]

Nvidia’s backing highlights growing confidence in AI-powered biotech stocks.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

Futures fell as AI leaders Micron, Sandisk and more keep sliding. Home Depot beat views while Google I/O kicks off.

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Amgen Inc. (NASDAQ:AMGN) is included among the 10 Best “Dogs of the Dow” Stocks to Buy for the Rest of 2026. On May 14, Piper Sandler lowered its price recommendation on Amgen Inc. (NASDAQ:AMGN) to $427 from $432. It reiterated an Overweight rating on the stock. The firm said that, from a broader business perspective, […]

(Updates with response from a Amgen spokesperson in the fourth, fifth and sixth paragraphs.) Amge

Amgen Inc.’s (NASDAQ:AMGN) Japanese partner Kissei Pharmaceutical Co., Ltd. said it has started information-sharing activities in Japan, urging healthcare professionals to carefully evaluate the use of Tavneos (avacopan) following safety and regulatory concerns raised in the U.S. and Europe. Kissei Advises Doctors To Exercise Caution On Tavneos The company said physicians should avoid prescribing the drug to new patients and reassess continued treatment for current users while considering risks

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.

Honeywell was added to the Dow for its tech focus and diversification across different end markets.

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The latest fair value estimate for Amgen has shifted slightly, from US$350.03 to US$349.66, keeping modeled upside closely aligned with prior assumptions. That small adjustment fits with recent analyst commentary, where higher and lower price targets have been clustering around the current trading range as views on growth and execution remain mixed. As you read on, you will see how to track these changing signals and what they might mean for following Amgen’s evolving story over time. Stay...

↘️ Intel (INTC), Nvidia (NVDA), Advanced Micro Devices (AMD): Chip stocks retreated premarket, following a ferocious rally in their shares. Intel, whose shares are up more than 200% this year through Thursday, is among the hardest hit, falling more than 4%.

If you are wondering whether Amgen’s current share price reflects its true worth, starting with a clear look at what the market is paying for its fundamentals can help ground your view. The stock last closed at US$336.23, with returns of 2.2% over the past week, a decline of 4.2% over the past month, a 2.6% gain year to date and a 28.6% gain over the past year. The 3 year and 5 year returns sit at 64.4% and 56.2% respectively. Recent price moves sit against a backdrop of ongoing product...

Investors need to pay close attention to AMGN stock based on the movements in the options market lately.

The agency's new initiative promises faster drug approval times, but smaller trial sponsors could struggle to keep up.

The Dow Jones Industrial Average would be even higher if it had more exposure to energy stocks.

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

The U.S. FDA recently highlighted Amgen’s role in its real‑time clinical trials initiative, confirming the initiation of Amgen’s Phase 1b STREAM-SCLC study in limited-stage small cell lung cancer using real-time data signal sharing. This positions Amgen at the forefront of emerging “continuous” trial frameworks that aim to shorten development timelines and could change how oncology drugs are tested and reviewed. We’ll now examine how Amgen’s early involvement in real-time oncology trials...

Amgen (NasdaqGS:AMGN) has been selected by the US Food and Drug Administration to participate in its real time clinical trials initiative. The company will apply the framework to its Phase 1b STREAM SCLC trial in small cell lung carcinoma. The initiative enables the FDA to receive trial data signals in real time, with the goal of improving trial efficiency and drug development timelines. Amgen focuses on biotechnology driven therapies, including oncology, where clinical trial design and...

They can weather many storms.

Amgen announced a $300 million expansion of its U.S. biologics manufacturing network. The plan includes a significant new investment in a Puerto Rico facility to scale next generation technologies. The move is intended to support domestic medicine production and strengthen the American supply chain. For investors tracking NasdaqGS:AMGN, this manufacturing build out adds an operational angle to a stock that is currently trading at $329.59. Over the past year, the share price return of 25.7%...

RPRX vs. AMGN: Which Stock Is the Better Value Option?

Viridian Therapeutics unveiled solid results Tuesday for its experimental eye disease treatment, a potential rival to Amgen.

Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.